Welcome to our dedicated page for Brainstorm Cell Therapeutics I news (Ticker: BCLI), a resource for investors and traders seeking the latest updates and insights on Brainstorm Cell Therapeutics I stock.
BrainStorm Cell Therapeutics Inc. (BCLI) generates a steady flow of news centered on its NurOwn® autologous stem cell platform for neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). Company press releases highlight clinical milestones, regulatory interactions, financing developments, and scientific presentations that shape the outlook for its lead investigational therapy.
News coverage frequently focuses on clinical trial progress for NurOwn, including the completed Phase 3 ALS study and preparations for the Phase 3b ENDURANCE trial under a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration. Updates describe FDA clearance to initiate the Phase 3b trial, submission of an IND amendment, listing of the study on ClinicalTrials.gov, and operational steps such as site activation and manufacturing readiness.
Investors and observers will also find data-driven announcements, such as survival results from BrainStorm’s Expanded Access Program in ALS and pharmacogenomic and biomarker analyses presented at scientific meetings. These releases detail how NurOwn-treated cohorts performed relative to published ALS survival estimates and discuss factors like the UNC13A genotype and cerebrospinal fluid biomarker pathways.
Additional news items cover regulatory and community developments, including the FDA’s consideration of a Citizen Petition requesting renewed review of NurOwn data, as well as BrainStorm’s engagement with the ALS community. Financial results and capital-raising activities are reported through quarterly earnings releases and 8-K filings, alongside information about promissory and convertible promissory notes.
Stock Titan’s BCLI news page aggregates these company-issued updates and related coverage, allowing readers to follow clinical, regulatory, scientific, and financing events that may influence BrainStorm’s development trajectory. For those tracking BCLI, this page offers a single location to review the latest disclosed information on NurOwn, ALS and MS programs, manufacturing partnerships, and listing status changes.
On September 30, 2020, BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) presented a poster on the Phase 3 clinical trial design of NurOwn® for ALS at the virtual Annual Northeast ALS Meeting. The trial is designed to evaluate the effects of NurOwn® on rapidly progressing ALS patients, building on promising Phase 2 results. The study aims to confirm the efficacy of NurOwn® and assess its duration through repeated administrations. Topline data from the trial is expected in Q4 2020, marking a significant step towards potential FDA approval.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) announced the appointment of William K. White as Senior Vice President, Head of Market Access and Pricing. With over 25 years of experience in product commercialization, White aims to ensure market access for NurOwn®, currently in a Phase 3 trial for ALS. CEO Chaim Lebovits emphasized the importance of White's background in securing patient access to innovative therapies, crucial for the potential FDA approval of NurOwn®. The company is focused on bringing revolutionary stem cell treatments to patients suffering from neurodegenerative diseases.
Brainstorm Cell Therapeutics (NASDAQ: BCLI) announced the granting of a new patent by the Japanese Patent Office for its method of generating mesenchymal stem cells secreting neurotrophic factors, crucial for treating neurodegenerative diseases. The patent covers key neurotrophic factors such as BDNF, GDNF, HGF, and VEGF. This development strengthens Brainstorm’s intellectual property portfolio, enhances its ability to secure commercial partnerships in Japan, and supports its ongoing Phase 3 trial for ALS treatment. The company aims to leverage this patent for strategic growth and market presence.
On August 25, 2020, BrainStorm Cell Therapeutics (NASDAQ: BCLI) announced the acceptance of a clinical abstract showcasing a correlation between MRI measures and functional improvements in patients with progressive multiple sclerosis (MS). This data will be presented at the MSVirtual2020 meeting on September 11-13. The analysis involved 48 participants and revealed significant differences in MRI data between those with improved versus stable or worsening function, specifically using the 9-hole peg test and timed-25-foot-walk metrics. CEO Chaim Lebovits emphasized the potential implications for clinical outcomes in their ongoing Phase 2 trial of NurOwn®.
On August 19, 2020, BrainStorm Cell Therapeutics (NASDAQ: BCLI) announced the publication of a manuscript regarding the effects of its NurOwn stem cell therapy on T and B regulatory cells in ALS. The research highlighted significant findings, including a notable reduction in inflammatory biomarkers and increased circulating T regulatory cells in previous clinical studies. The preclinical experiments demonstrated a decrease in interferon-g secretion and induction of regulatory cells, which may support NurOwn's therapeutic potential in ALS and other neuroinflammatory diseases.
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) announced that Dr. Ralph Kern will present a corporate overview at the 40th Annual Canaccord Genuity Growth Conference, held virtually from August 11-13, 2020. One-on-one meetings with institutional investors will also be available on the presentation day. The event will take place on August 13, 2020, at 3:30 PM ET, with a webcast accessible for viewing. BrainStorm develops adult stem cell therapies, notably its MSC-NTF cells for ALS, which have received Orphan Drug status from the FDA and EMA. Phase 3 trials are ongoing, aiming for FDA approval.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) reported its Q2 2020 financial results, highlighting a net loss of $7.39 million, up from $4.90 million in Q2 2019. Despite COVID-19 challenges, the firm completed enrollment in its Phase 3 ALS trial, with data expected by November 2020. BCLI is also advancing its NurOwn platform into new areas, including Alzheimer's, with a Phase 2 trial planned in Europe. The company has approximately $37.5 million in available funding as of July 31, 2020, reflecting growth from prior periods.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) will hold a conference call on August 5, 2020, at 8:00 a.m. EDT to update shareholders on its Q2 financial results and provide corporate updates. CEO Chaim Lebovits will discuss the timeline for the Phase 3 trial of NurOwn® in ALS while Dr. Revital Aricha will cover recent advancements in R&D, including a preclinical study on COVID-19 treatment. The company has recently completed enrollment for its pivotal ALS trial and received FDA clearance for a Phase 2 trial in progressive MS.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) announced progress in its development of an innovative exosome-based platform technology targeting severe COVID-19 infection. Key findings from a mouse model study showed that intratracheal administration of exosomes derived from MSCs using NurOwn® technology led to significant improvements in lung parameters, including functional recovery and reduced lung damage. The company plans to discuss the results during its Q2 earnings call on August 5 and is considering a clinical trial for ARDS based on these promising preclinical results.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) is hosting a Key Opinion Leader webinar regarding its Alzheimer's Disease (AD) program today at 8:15 AM ET. The company is expanding its clinical pipeline to develop NurOwn and is initiating a Phase 2 study in AD. This 52-week, open-label trial will evaluate NurOwn in 40 participants with prodromal to mild AD at leading medical centers in the Netherlands and France. The webinar features insights from prominent researchers, aiming to provide an overview of the trial's goals and implications for Alzheimer's treatment.